SomaLogic of Boulder, Colo., has received US Patent No. 7,709,192, "Nucleic acid ligand diagnostic biochip." The patent describes a nucleic acid ligand biochip that consists of a solid support to which one or more specific nucleic acid ligands is attached. Each nucleic acid ligand binds to a particular target molecule contained within a test mixture, such as a bodily fluid. The target molecules include proteins, hormones, sugars, metabolic byproducts, cofactor, and intermediates, drugs, and toxins.